Biogen Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2025: 8.97%

Biogen Inc. Return on Equity (ROE) is 8.97% for the Trailing 12 Months (TTM) ending March 31, 2025, a 13.38% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Biogen Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2024 was 7.91%, a -67.24% change year over year.
  • Biogen Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2023 was 24.16%, a 80.47% change year over year.
  • Biogen Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2022 was 13.39%, a -51.72% change year over year.
  • Biogen Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2021 was 27.73%, a -37.70% change year over year.
Key Data
Date Return on Equity (ROE) Return on Assets (ROA) Revenue Per Share Free Cash Flow Per Share